{
    "Trade/Device Name(s)": [
        "ADVIA\u00ae Chemistry Total Bilirubin_2 (TBIL_2)",
        "TBIL_2"
    ],
    "Submitter Information": "Siemens Healthcare Diagnostics Inc.",
    "510(k) Number": "K170065",
    "Predicate Device Reference 510(k) Number(s)": [
        "K150510"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "JFM",
        "MQM"
    ],
    "Summary Letter Date": "March 9, 2017",
    "Summary Letter Received Date": "January 9, 2017",
    "Submission Date": "January 6, 2017",
    "Regulation Number(s)": [
        "21 CFR 862.1110",
        "21 CFR 862.1113"
    ],
    "Regulation Name(s)": [
        "Bilirubin (total or direct) test system",
        "Bilirubin (total and unbound) in the neonate system"
    ],
    "Analyte Class(es)": [
        "chemistry"
    ],
    "Analyte(s)": [
        "Total Bilirubin"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Plasma"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "ADVIA\u00ae Chemistry systems",
        "ADVIA\u00ae Chemistry 1800 System",
        "ADVIA\u00ae Chemistry 1650 System"
    ],
    "Method(s)/Technology(ies)": [
        "Chemical oxidation using vanadate",
        "Colorimetric (end-point) measurement"
    ],
    "Methodologies": [
        "Chemical oxidation",
        "Colorimetric assay"
    ],
    "Submission Type(s)": [
        "Reagent",
        "Kit"
    ],
    "Document Summary": "FDA 510(k) summary for Siemens ADVIA\u00ae Chemistry Total Bilirubin_2 (TBIL_2) assay using chemical oxidation for quantitative measurement of total bilirubin in serum and plasma.",
    "Indications for Use Summary": "For in vitro diagnostic quantitative determination of total bilirubin in serum and plasma of adults and neonates on ADVIA\u00ae Chemistry systems to aid in the diagnosis and treatment of liver, hemolytic hematological, and metabolic disorders, and to assess risk of bilirubin encephalopathy (kernicterus) in newborns.",
    "fda_folder": "Clinical Chemistry"
}